BRPI0506977A - composto de tetrahidrocarbolina como agentes anticáncer - Google Patents

composto de tetrahidrocarbolina como agentes anticáncer

Info

Publication number
BRPI0506977A
BRPI0506977A BRPI0506977-7A BRPI0506977A BRPI0506977A BR PI0506977 A BRPI0506977 A BR PI0506977A BR PI0506977 A BRPI0506977 A BR PI0506977A BR PI0506977 A BRPI0506977 A BR PI0506977A
Authority
BR
Brazil
Prior art keywords
tetrahydrocarboline
compound
anticancer agents
alone
pharmaceutically acceptable
Prior art date
Application number
BRPI0506977-7A
Other languages
English (en)
Inventor
Weibo Wang
Zhi-Jie Ni
Paul Barsanti
Yi Xia
Nathan Brammeier
Megan Treutle
Elisa Jazan
Kelly Wayman
David Dibble
Jie-Kai Cheng
Sabina Pecchi
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of BRPI0506977A publication Critical patent/BRPI0506977A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTOS DE TETRAHIDROCARBOLINA COMO AGENTES ANTICáNCER. Composto de tetrahidrocarbolina, sais, e prómedicamentos farmaceuticamente aceitáveis desses; composições que incluem um veículo farmaceuticamente aceitável e um ou mais dos compostos de tetrahidrocarbolina, isoladamente ou em combinação com pelo menos um agente terapêutico adicional. Métodos de uso dos compostos de tetrahidrocarbolina, isoladamente ou em combinação com pelo menos um agente terapêutico adicional, na profilaxia ou tratamento de doenças proliferativas.
BRPI0506977-7A 2004-01-23 2005-01-24 composto de tetrahidrocarbolina como agentes anticáncer BRPI0506977A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53898004P 2004-01-23 2004-01-23
PCT/US2005/002270 WO2005070930A2 (en) 2004-01-23 2005-01-24 Tetrahydrocarboline compounds as anticancer agents

Publications (1)

Publication Number Publication Date
BRPI0506977A true BRPI0506977A (pt) 2007-07-03

Family

ID=34807249

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506977-7A BRPI0506977A (pt) 2004-01-23 2005-01-24 composto de tetrahidrocarbolina como agentes anticáncer

Country Status (9)

Country Link
US (1) US7855295B2 (pt)
EP (1) EP1706404A2 (pt)
JP (1) JP2007518822A (pt)
CN (1) CN1910183A (pt)
AU (1) AU2005206570A1 (pt)
BR (1) BRPI0506977A (pt)
CA (1) CA2554150A1 (pt)
MX (1) MXPA06008211A (pt)
WO (1) WO2005070930A2 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1637521B1 (en) * 2003-06-23 2013-06-19 Ono Pharmaceutical Co., Ltd. Novel tricyclic heterocycle compound
JP4857452B2 (ja) 2004-03-15 2012-01-18 ピーティーシー セラピューティクス，インコーポレーテッド 血管新生の抑制に有用なカルボリン誘導体
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
JP4997976B2 (ja) 2004-12-22 2012-08-15 小野薬品工業株式会社 三環式化合物およびその用途
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
WO2008103470A2 (en) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
EP2214485B1 (en) * 2007-09-25 2016-07-20 Minerva Biotechnologies Corp. Methods for treatment of cancer
EP2050747A1 (en) * 2007-10-12 2009-04-22 BioAlliance Pharma Dimers of harmol or of its derivatives and uses thereof
JP5501251B2 (ja) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
CN101591348B (zh) * 2008-05-30 2011-07-27 首都医科大学 四氢咔啉酰氨基酸苄酯及其制备方法和应用
CN101597289B (zh) * 2008-06-02 2011-09-21 首都医科大学 2-色氨酰-β-四氢咔啉-3-甲酰基氨基酸苄酯及其制备方法和应用
EP3718405A1 (en) 2009-05-27 2020-10-07 PTC Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
US8703726B2 (en) 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
JP2012528181A (ja) 2009-05-27 2012-11-12 ピーティーシー セラピューティクス，インコーポレーテッド 置換テトラヒドロβ−カルボリンの製造方法
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
NZ603575A (en) * 2010-07-06 2014-03-28 Ono Pharmaceutical Co Tetrahydrocarboline derivative
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2012127885A1 (ja) 2011-03-18 2012-09-27 小野薬品工業株式会社 テトラヒドロカルボリン誘導体
US9394296B2 (en) * 2012-01-09 2016-07-19 X-Chem, Inc. Tryptoline derivatives having kinase inhibitory activity and uses thereof
CN103087062B (zh) * 2013-01-19 2015-06-03 安徽师范大学 N-磺酰基取代-β-四氢咔啉衍生物的制备方法
UY35590A (es) * 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
CA2999503A1 (en) * 2015-09-23 2017-03-30 Minerva Biotechnologies Corporation Method of screening for agents for differentiating stem cells
JP2019001715A (ja) * 2015-10-30 2019-01-10 協和発酵キリン株式会社 三環性化合物
EP3378861B1 (en) * 2015-11-12 2021-08-04 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
CN106967063B (zh) * 2017-03-21 2019-01-11 浙江大学 1-三氟甲基-1,2,3,4-四氢-β-咔啉衍生物及其制备方法
KR20200035292A (ko) 2017-08-01 2020-04-02 피티씨 테라퓨틱스, 인크. 혈액 암 치료에 사용하기 위한 dhodh 억제제
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
CN110791389B (zh) * 2019-09-30 2021-06-01 义乌欧风汽车用品有限公司 一种除胶剂及其制备方法和应用
CA3237691A1 (en) * 2021-12-31 2023-07-06 Ptc Therapeutics, Inc. Carboline compounds and use thereof
WO2024099898A1 (en) * 2022-11-07 2024-05-16 Merck Patent Gmbh Substituted bi-and tricyclic hset inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300541B1 (en) 1987-07-20 1996-03-27 Duphar International Research B.V 8,9-anellated-1,2,3,4-tetrahydro-beta-carboline derivatives
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
JPH03287586A (ja) 1990-04-02 1991-12-18 Taisho Pharmaceut Co Ltd テトラヒドロ―β―カルボリン誘導体
JP3287586B2 (ja) 1991-07-09 2002-06-04 キヤノン株式会社 カラー画像処理方法、及びカラー画像処理装置
US5206377A (en) * 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
US5622960A (en) 1992-04-14 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Topoisomerase II inhibitors and therapeutic uses therefor
ES2169857T3 (es) * 1996-04-04 2002-07-16 Hoffmann La Roche Uso de derivados de tetrahidro-beta-carbolinas como agentes antimetastaticos.
FR2796644B1 (fr) 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US6720331B2 (en) * 2001-04-03 2004-04-13 National Sun Yat-Sen University 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents
US6933303B2 (en) 2001-10-19 2005-08-23 Transtech Pharma, Inc. Heteroaryl-fused nitrogen heterocycles as therapeutic agents

Also Published As

Publication number Publication date
WO2005070930A2 (en) 2005-08-04
CA2554150A1 (en) 2005-08-04
EP1706404A2 (en) 2006-10-04
US7855295B2 (en) 2010-12-21
WO2005070930A3 (en) 2006-01-19
JP2007518822A (ja) 2007-07-12
US20050215580A1 (en) 2005-09-29
MXPA06008211A (es) 2006-08-31
AU2005206570A1 (en) 2005-08-04
CN1910183A (zh) 2007-02-07

Similar Documents

Publication Publication Date Title
BRPI0506977A (pt) composto de tetrahidrocarbolina como agentes anticáncer
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
TW200718689A (en) 2-Amino-quinazolin-5-ones
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
ECSP099387A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
DE602004025698D1 (de) PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
WO2004006859A3 (en) Platinum compound
BRPI0707189A8 (pt) derivados de pirimidina utilizados como inibidores de pi-3 cinase
BRPI0510684A (pt) composições para adiministração tópica ou transdérmica de agente anticolinérgico ou antiespasmódico e uso dos respectivos compostos
MY141025A (en) Dose forms
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
BRPI0414114A (pt) uso de defibrotide, formulação, e, método para tratar um mamìfero afetado por um tumor
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
AR050574A1 (es) Uso de un compuesto para estimulacion del crecimiento de pelo
AR040287A1 (es) Plataforma para formulaciones transdermicas (pft)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US)

Free format text: ALTERADO DE: CHIRON CORPORATION

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.